EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Behavioural support and nicotine replacement therapy for smokeless tobacco cessation in Bangladesh, India and Pakistan: A pilot randomized controlled trial

Faraz Siddiqui iD, Mona Kanaan, Ray Croucher, Linda Bauld, Fariza Fieroze, Prashant Kumar, Laraib Mazhar, Varsha Pandey, Cath Jackson, Rumana Huque, Romaina Iqbal, Kamran Siddiqi iD und 1 weitere

Addiction · 2024

DOI: 10.1111/add.16515 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Addiction, 2024. Verfasst von Faraz Siddiqui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of York, York, UK. Hauptthemen laut MEDLINE: Tobacco Use Cessation, Tobacco Use Cessation Devices, Tobacco, Smokeless. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health and Care Research, Economic and Social Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Smokeless tobacco (ST) use in South Asia is high, yet interventions to support its cessation are lacking. We tested the feasibility of delivering interventions for ST cessation in South Asia.

Design

We used a 2 × 2 factorial design, pilot randomized controlled trial with a duration of 26 weeks, including baseline and follow‐up (6, 12 and 26 weeks) assessments.

Setting

Two primary health‐care facilities each in Dhaka (Bangladesh) and Karachi (Pakistan) and a walk‐in cancer screening clinic in Noida (India) took part.

Participants

Adult daily ST users willing to make a quit attempt within 30 days. Of 392 screened, 264 participants [mean age: 35 years, standard deviation = 12.5, 140 (53%) male] were recruited between December 2020 and December 2021; 132 from Bangladesh, 44 from India and 88 from Pakistan.

Interventions

Participants were randomized to one of three treatment options [8‐week support through nicotine replacement therapy (NRT, n = 66), a behavioural intervention for smokeless tobacco cessation in adults (BISCA, n = 66) or their combination ( n = 66)] or the control condition of very brief advice (VBA) to quit ( n = 66).

Measurements

Recruitment and retention, data completeness and feasibility of intervention delivery were evaluated. Biochemically verified abstinence from tobacco, using salivary cotinine, was measured at 26 weeks.

Findings

Retention rates were 94.7% at 6 weeks, dropping to 89.4% at 26 weeks. Attendance in BISCA pre‐quit (100%) and quit sessions (86.3%) was high, but lower in post‐quit sessions (65.9%), with variability among countries. Adherence to NRT also varied (45.5% Bangladesh, 90% India). Data completion for key variables exceeded 93% among time‐points, except at 26 weeks for questions on nicotine dependence (90%), urges (89%) and saliva samples (62.7%). Among follow‐up time‐points, self‐reported abstinence was generally higher among participants receiving BISCA and/or NRT. At 26 weeks, biochemically verified abstinence was observed among 16 (12.1%) participants receiving BISCA and 13 (9.8%) participants receiving NRT.

Conclusions

This multi‐country pilot randomized controlled trial of tobacco cessation among adult smokeless tobacco users in South Asia demonstrated the ability to recruit and retain participants and report abstinence, suggesting that a future definitive smokeless tobacco cessation trial is viable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tobacco Use CessationTobacco Use Cessation DevicesTobacco, SmokelessHumansBangladeshMaleIndiaAdultPilot ProjectsFemalePakistanBehavior TherapyMiddle AgedFeasibility StudiesNicotine Replacement Therapy

Stichwörter der Autor:innen

Behavioural supportSouth Asianicotine replacementpilot trialsmokeless tobaccotobacco cessation

Autor:innen und Institutionen

  • Department of Health Sciences, University of York, York, UK.
  • Usher Institute and Behavioural Research UK, University of Edinburgh, Edinburgh, UK.
  • ARK Foundation, Dhaka, Bangladesh.
  • National Institute of Cancer Prevention Research, Noida, India.
  • Aga Khan University, Karachi, Pakistan.
  • Valid Research Ltd, Wetherby, UK.

ORCID-Profile: Faraz Siddiqui, Kamran Siddiqi

Förderung

  • National Institute of Health and Care Research
  • Economic and Social Research Council

Zitieren

APA

Siddiqui, F., Kanaan, M., Croucher, R., Bauld, L., Fieroze, F., Kumar, P., Mazhar, L., Pandey, V., Jackson, C., Huque, R., Iqbal, R., Siddiqi, K., & ASTRA Global Health Research Group (2024). Behavioural support and nicotine replacement therapy for smokeless tobacco cessation in Bangladesh, India and Pakistan: A pilot randomized controlled trial. Addiction. https://doi.org/10.1111/add.16515

Vancouver

Siddiqui F, Kanaan M, Croucher R, Bauld L, Fieroze F, Kumar P, et al. Behavioural support and nicotine replacement therapy for smokeless tobacco cessation in Bangladesh, India and Pakistan: A pilot randomized controlled trial. Addiction. 2024. doi:10.1111/add.16515

BibTeX
@article{Siddiqui2024,
  author = {Siddiqui, Faraz and Kanaan, Mona and Croucher, Ray and Bauld, Linda and Fieroze, Fariza and Kumar, Prashant and Mazhar, Laraib and Pandey, Varsha and Jackson, Cath and Huque, Rumana and Iqbal, Romaina and Siddiqi, Kamran and ASTRA Global Health Research Group, ASTRA Global Health Research Group},
  title = {Behavioural support and nicotine replacement therapy for smokeless tobacco cessation in Bangladesh, India and Pakistan: A pilot randomized controlled trial},
  journal = {Addiction},
  year = {2024},
  doi = {10.1111/add.16515}
}
Kostenlos starten →